Nice, FRANCE - 17 Jun `19Glisodin with UVB

Official Title: Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo. A Randomized Double Blind Placebo Controlled Monocentric Study

In Brief: Glisodin 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months

Ages Eligible:  18 Years and older

Start Date: June 17, 2019

Completion Date (estimated): November 2, 2020

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT03941808

Location: Centre Hospitalier Universitaire de Nice at Nice, Alpes-Maritime, France, 06001

Contact: To learn more about this study, you or your doctor may contact Passeron Thierry, PhD by phone +33492034688 or email passeron.t@chu-nice.fr. Please refer to this study by its NCT number.         

FAQOther Questions

  • Isn't it just a cosmetic disorder?

    Contrary to popular belief, vitiligo is not a cosmetic disorder but a systemic disease affecting the largest body organ and other vital systems, with multiple comorbidities. Fo...

  • Who is prone to vitiligo?

    Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...

  • Which diseases most commonly accompany vitiligo?

    According to a 10-year study, vitiligo patients have a statistically significant higher prevalence of other autoimmune conditions and dermatological disorders: hypothyroidism...